Department of Radiotherapy, University Hospital Leuven, Leuven, Belgium.
Radiother Oncol. 2010 May;95(2):149-52. doi: 10.1016/j.radonc.2010.01.012. Epub 2010 Feb 18.
This paper reports on an evaluation of 5 RapidArc optimization approaches vs IMRT. This study includes 11 patients with adenocarcinoma of the prostate. Rectal Normal Tissue Complication Probability is used as a constraint in a dose escalation. RapidArc rectal NTCP's are lower than those of IMRT (p = 0.007). This allows a mean dose escalation of 2.1 Gy([0.7 Gy,3.5 Gy]).
本文报告了 5 种 RapidArc 优化方法与调强放疗(IMRT)的对比评估。该研究纳入了 11 例前列腺腺癌患者。直肠正常组织并发症概率(rectal normal tissue complication probability,NTCP)被用作剂量递增的限制条件。RapidArc 的直肠 NTCP 低于 IMRT(p=0.007)。这使得平均剂量递增 2.1Gy([0.7Gy,3.5Gy])成为可能。